Dr. Swayampakula Ramakanth
Recent Articles about Elevation Oncology Inc.
Boston Biotech Reports Promising Interim Data 08/07/2024
Interim efficacy data reported for Elevation Oncology Inc.'s (ELEV:NASDAQ) EO-3021 as a monotherapy is competitive and potentially could be superior as a combination therapy, according to an H.C. Wainwright & Co. research note.
© 2024 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
